09.05.12
CMIC CMO USA received qualification of three new development suites at their FDA registered site in Cranbury, NJ. Gary Wada, executive vice president and general manager said, “The increased capacity will allow us to initiate development projects quickly and reduce the time for our clients to initiate clinical trials and file for regulatory approval.”
Also, Jeffrey Dopf has been named director of business development. Mr. Dopf served most recently as a business development manager with Glatt Pharmaceutical Services and was previously with Patheon.
“I am thrilled to be joining CMIC at this exciting time, as they reaffirm their commitment to growth and increased client services to the pharmaceutical industry,” said Mr. Dopf.
Also, Jeffrey Dopf has been named director of business development. Mr. Dopf served most recently as a business development manager with Glatt Pharmaceutical Services and was previously with Patheon.
“I am thrilled to be joining CMIC at this exciting time, as they reaffirm their commitment to growth and increased client services to the pharmaceutical industry,” said Mr. Dopf.
